Microbial-derived bile acid reverses inflammation in IBD via GPBAR1 agonism and RORγt inverse agonism
Michele Biagioli, Cristina Di Giorgio, Carmen Massa, Silvia Marchianò, Rachele Bellini, Martina Bordoni, Ginevra Urbani, Rosalinda Roselli, Ginevra Lachi, Elva Morretta, Fabrizio Dal Piaz, Bruno Charlier, Bianca Fiorillo, Bruno Catalanotti, Luigi Cari, Giuseppe Nocentini, Patrizia Ricci, Eleonora Distrutti, Carmen Festa, Valentina Sepe, Angela Zampella, Maria Chiara Monti, Stefano Fiorucci
Abstract
The interplay between the dysbiotic microbiota and bile acids is a critical determinant for development of a dysregulated immune system in inflammatory bowel disease (IBD). Here we have investigated the fecal bile acid metabolome, gut microbiota composition, and immune responses in IBD patients and murine models of colitis and found that IBD associates with an elevated excretion of primary bile acids while secondary, allo- and oxo- bile acids were reduced. These changes correlated with the disease severity, mucosal expression of pro-inflammatory cytokines and chemokines, and reduced inflow of anti-inflammatory macrophages and Treg in the gut. Analysis of bile acids metabolome in the feces allowed the identification of five bile acids: 3-oxo-DCA, 3-oxo-LCA, allo-LCA, iso-allo-LCA and 3-oxo-UDCA, whose excretion was selectively decreased in IBD patients and diseased mice. By transactivation assay and docking calculations all five bile acids were shown to act as GPBAR1 agonists and RORγt inverse agonists, skewing Th17/Treg ratio and macrophage polarization toward an M2 phenotype. In a murine model of colitis, administration of 3-oxo-DCA suffices to reverse colitis development and intestinal dysbiosis in a GPBAR1-dependent manner. In vivo administration of 3-oxo-DCA to colitic mice also reverses disease severity and RORγt activation induced by a RORγt agonist and IL-23, a Th17 inducing cytokine. These results demonstrated that intestinal excretion of 3-oxoDCA, a dual GPBAR1 agonist and RORγt inverse agonist, is reduced in IBD and in models of colitis and its restitution protects against colitis development, highlighting a potential role for this agent in IBD management. • IBD severity links to reduced oxo- and allo-bile acid excretion. • Targeting bile acid pathways offers novel IBD therapeutic strategies. • 3-oxo-DCA acts as a dual GPBAR1 agonist and RORγt inverse agonist. • 3-oxo-DCA reverses dysbiosis and inflammation in preclinical IBD models. • 3-oxo-DCA alleviates colitis by modulating macrophages and Th17/Treg balance.